SOPHiA GENETICS SA Ordinary Shares Q3 2025 Earnings Recap

SOPH Q3 2025 November 4, 2025

Get alerts when SOPH reports next quarter

SOPHiA GENETICS delivered a strong Q3 2025 performance with 23% year-over-year revenue growth, driven by record new customer signings and sustained momentum in the U.S. market, prompting the company to raise its revenue guidance for the year.

Earnings Per Share Miss

$-0.30 vs $-0.20 est.

-50.0% surprise

Revenue Miss

19462000 vs 20493750 est.

-5.0% surprise

Market Reaction

1-Day -6.4%

5-Day -12.6%

30-Day -1.6%

See SOPH alongside your other holdings

Add to your portfolio — free

Key Takeaways

New customer signings reached 31 in Q3, bringing the total for 2025 to 94, surpassing last year’s total.
U.S. revenue grew 30% year-over-year as new strategic partnerships with major health systems were established.
The launch and global adoption of the liquid biopsy application MSK-ACCESS has seen more than 60 customers signed, with significant backing from AstraZeneca for its deployment.
SOPHiA's innovative Digital Twins technology aims to enhance treatment decision-making by leveraging multimodal data for oncology.
Full-year revenue guidance is now set between $75 million and $77 million, reflecting strong business momentum.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit SOPH on AllInvestView.